AKBA
Akebia TherNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$353.60M
P/E Ratio
—
EPS
$-0.02
Beta
0.37
52W High
$4.08
52W Low
$1.14
50-Day MA
$1.36
200-Day MA
$2.32
Dividend Yield
—
Profit Margin
-2.26%
Forward P/E
34.48
PEG Ratio
0.00
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $236.20M |
| Gross Profit (TTM) | $195.84M |
| EBITDA | $27.27M |
| Operating Margin | -10.50% |
| Return on Equity | -553.00% |
| Return on Assets | 5.44% |
| Revenue/Share (TTM) | $0.92 |
| Book Value | $0.12 |
| Price-to-Book | 11.34 |
| Price-to-Sales (TTM) | 1.50 |
| EV/Revenue | 1.002 |
| EV/EBITDA | 10.89 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.90% |
| Shares Outstanding | $267.88M |
| Float | $262.21M |
| % Insiders | 4.07% |
| % Institutions | 47.57% |
Analyst Ratings
Consensus ($4.40 target)
1
Strong Buy4
BuyData last updated: 4/7/2026